 6. Has received prior therapy with an anti-PD1, anti-PDL1, anti-CD137, anti-cytotoxic T-lymphocyte-associated antigen-4 CTLA-4 antibody including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways or anti-PDL2 agent. 